Published in Physiol Rep on July 03, 2014
Exome Array Analysis Identifies a Common Variant in IL27 Associated with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2016) 0.81
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86
Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med (1995) 33.41
Regulatory T cells and immune tolerance. Cell (2008) 18.77
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J (2004) 16.84
Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med (2008) 4.33
Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med (2000) 4.32
Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med (2009) 4.27
Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest (2007) 4.21
The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol (2009) 3.72
A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature (1990) 3.10
Chemokine receptors: multifaceted therapeutic targets. Nat Rev Immunol (2002) 2.92
Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med (2010) 2.85
Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 2.80
Chronic obstructive pulmonary disease: thin-section CT measurement of airway wall thickness and lung attenuation. Radiology (2005) 2.37
Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest (2000) 2.35
The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med (2002) 2.29
The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD (2010) 1.59
New directions in the basic and translational biology of interleukin-27. Trends Immunol (2011) 1.54
Human airway narrowing measured using high resolution computed tomography. Am J Respir Crit Care Med (1996) 1.37
Time course and pattern of COPD exacerbation onset. Thorax (2011) 1.30
Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA (1999) 1.28
TSG-6 protein is crucial for the development of pulmonary hyaluronan deposition, eosinophilia, and airway hyperresponsiveness in a murine model of asthma. J Biol Chem (2012) 1.18
CD137-mediated immunotherapy for allergic asthma. J Clin Invest (2006) 1.13
Deletion polymorphism of SIGLEC14 and its functional implications. Glycobiology (2009) 1.07
Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med (1998) 1.07
Systemic biomarkers in exacerbations of COPD: the evolving clinical challenge. Chest (2011) 1.04
Tumor necrosis factor-stimulated gene-6 (TSG-6) amplifies hyaluronan synthesis by airway smooth muscle cells. J Biol Chem (2012) 1.03
Association of interleukin (IL)-12 and IL-27 gene polymorphisms with chronic obstructive pulmonary disease in a Chinese population. DNA Cell Biol (2008) 1.01
A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations. Int J Chron Obstruct Pulmon Dis (2013) 0.99
Tc2 response at the onset of COPD exacerbations. Chest (2008) 0.95
Overview of the mechanisms regulating chemokine activity and availability. Immunol Lett (2012) 0.95
Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation. Cell Mol Life Sci (2013) 0.94
Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. Respir Med (2004) 0.90
IL-27 is elevated in patients with COPD and patients with pulmonary TB and induces human bronchial epithelial cells to produce CXCL10. Chest (2011) 0.88
Aα-Val360: a marker of neutrophil elastase and COPD disease activity. Eur Respir J (2012) 0.86
Heparan sulfates in the lung: structure, diversity, and role in pulmonary emphysema. Anat Rec (Hoboken) (2010) 0.83
The fibrinogen cleavage product Aα-Val360, a specific marker of neutrophil elastase activity in vivo. Thorax (2011) 0.82
Mechanisms of exacerbations. Novartis Found Symp (2001) 0.79
Biomarkers in acute exacerbation of chronic obstructive pulmonary disease: among the blind, the one-eyed is king. Am J Respir Crit Care Med (2006) 0.78
Influence of SIGLEC9 polymorphisms on COPD phenotypes including exacerbation frequency. Respirology (2016) 0.75